Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Lumos Pharma (NASDAQ:LUMO) will present at the H.C. Wainwright Virtual BIOCONNECT Conference from January 10-13, 2022. The presentation will be available online starting at 7:00 AM ET on January 10. Interested parties can access the webcast through Lumos Pharma's website under the Investors & Media section and it will be archived for 90 days. Lumos Pharma focuses on developing therapeutics for rare diseases, with its lead candidate LUM-201 targeting Pediatric Growth Hormone Deficiency. LUM-201 is currently undergoing Phase 2 trials and has received Orphan Drug Designation in the US and EU.
- None.
- None.
AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: https://journey.ct.events/view/d2cd046c-ff2c-40ea-acdc-340df7150783 and on Lumos Pharma’s website in the Investors & Media section under “Events & Presentations.” This webcast will be archived for 90 days on the Company’s website.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
FAQ
When will Lumos Pharma present at the H.C. Wainwright Virtual BIOCONNECT Conference?
What is the purpose of Lumos Pharma's presentation at the conference?
How can I access the Lumos Pharma presentation?
What is LUM-201 and its significance for Lumos Pharma?
Has LUM-201 received any designations?
